On February 21, 2008 Shire announced its results for the same period
under US GAAP.

Notes to Editors

Shire plc

Shire's strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the
specialist physician. Shire focuses its business on attention deficit and
hyperactivity disorder (ADHD), human genetic therapies (HGT),
gastrointestinal (GI) and renal diseases. The structure is sufficiently
flexible to allow Shire to target new therapeutic areas to the extent
opportunities arise through acquisitions. Shire's in-licensing, merger and
acquisition efforts are focused on products in niche markets with strong
intellectual property protection either in the US or Europe. Shire believes
that a carefully selected portfolio of products with relatively small-scale
sales forces will deliver strong results.

The "Safe Harbor" Statement Under The Private Securities Litigation
Reform Act of 1995

Statements included herein that are not historical facts are
forward-looking statements. Such forward-looking statements involve a
number of risks and uncertainties and are subject to change at any time. In
the event such risks or uncertainties materialise, Shire's results could be
materially affected. The risks and uncertainties include, but are not
limited to, risks associated with: the inherent uncertainty of
pharmaceutical research; product development including, but not limited to,
the successful development of JUVISTA(R) (Human TGFbeta3) and velaglucerase
alfa (G'/>"/>

(Date:3/30/2015)... Multiple new research abstracts suggest walnuts may have ... From their impact on colon cancer and certain aspects ... gut health and vascular health, the research findings presented ... of walnuts, inner workings. Running March 28 through April ... meeting attracts an international audience of over 14,000 leading ...

(Date:3/30/2015)... US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; ... and Yale University, on March 27 released pre-clinical data ... as an oral presentation by Professor Gil Mor ... 62 nd Annual Scientific Meeting of the Society ... In both in vitro and ...

(Date:3/30/2015)... OTTAWA , March 30, 2015 /CNW/ - A ... today on the salaries and demographic profiles of new ... "Opening the Door – Building Careers for New Grads ... Canada,s Research-Based Pharmaceutical Companies (Rx&D) and features ... federal Career Focus wage subsidy program from 2013 to ...

... Oct. 18 Pharmion Corporation,(Nasdaq: PHRM ) will ... 31, 2007, after the close of the U.S. financial ... live audio,webcast to discuss the company,s results in greater ... 31, 2007. This call is being webcast by ...

... CLARA, Calif., Oct. 18 Coherent, Inc.,(Nasdaq: COHR ... after the market close and host a live webcast ... Wednesday, November 7,2007 at 4:30 p.m. ET. The ... can be accessed,at either http://www.coherent.com/Investors/ or ...

... KNOXVILLEThe National Science Foundation (NSF) has awarded $18.6 million ... Institute for Mathematical and Biological Synthesis (NIMBioS) to continue ... problems across biology, from the level of the genome ... next five years and renews the work of the ...

... a body is like building a houseif you compromise structural ... a cellular level than in the case of epithelial sheets, ... the gut to mammary glands. As long as epithelial cells ... of building tissue barriers and constructing ducts goes smoothly. But ...

... published in the July 17, issue of the journal ... forests in Malaysian Borneo have been heavily impacted by logging. ... were already thought to be global hotspots of forest loss ... the rates and patterns of change have remained poorly measured ...

... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: filling ...

... system automates the denaturation and hybridization steps ... convenience for clinical and research personnel. The ... of sample types, is easy to use, ... 50% while ensuring overall precision and accuracy ...

... L1210 cells were cultured in DMEM and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...